Arthur Stril
CFO & Chief Business OfficerMr. Arthur Stril was Interim CFO of Cellectis S.A. from May 2, 2024 to February 2025 and serves as its Chief Financial Officer & Chief Business Officer since February 2025 and had been its Chief Business Officer since September 2020 until May 20, 2024 and served as its Vice President of Corporate Development since July 2018 until September 2020. He joined Cellectis in July 2018 and is responsible for program management, strategy and business development. Mr. Stril began his career at the European Commission’s Directorate-General for Competition, controlling global pharmaceutical mergers such as the Novartis/GSK and Sanofi/Boehringer Ingelheim asset swaps, Pfizer’s acquisition of Hospira and Teva’s acquisition of Actavis Generics. He later became Head of the Hospital Financing unit at the French Ministry of Health, where he led a team responsible for the €80bn hospital budget. Since 2023, Mr. Stril serves on the board of directors of Primera Therapeutics as a director designated by the company. He graduated from Cambridge University with a Master of Mathematics and Master of Physics from the École Normale Supérieure, Paris and holds a diploma in Immunotherapy from the Université Paris-Descartes. He is also a member of the French Corps des Mines and is on the Board of Advisors of non-profit Life Science Cares.
Positions
- Company NameCellectis S.A.Stock CodeCLLSPositionCFO & Chief Business OfficerColleagues
- ACAndre ChoulikaCo-Founder, CEO & Director
- JGJean-Pierre GarnierIndependent Non-Executive Chairman
- DJDavid J. SourdiveCo-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director
- VCValerie CrosPrincipal Financial Officer & Principal Accounting Officer
- JCJean Charles EpinatChief Technological Officer
- ACAndre C. MullerIndependent Director
- LALaurent ArthaudDirector
